Anders Fasth comments: “I started treating children with rheumatism several decades ago. We today have effective medicines to choose from, but still many children have insufficient response. Therefore, it feels very stimulating to be closely involved in an exciting development concerning the treatment of inflammatory diseases and especially in children.”
Pre-clinical studies have shown very promising results and a unique mechanism of action that has the potential to provide better treatment of chronic inflammatory diseases. The lead candidate drug SOL-116 is a fully humanized monoclonal antibody. It is in production development and toxicological studies will be conducted during next year and clinical trials will be initiated during 2021.
“Our scientific advisory board is very committed and competent. In addition to ongoing contacts, we also gather for an annual workshop where current issues and the future are discussed. Anders has already been contributing during these and it is very gratifying that he now also joins the team. The scientific advisory board is an important resource for Lipum and the other members are professor Rikard Holmdahl, Dr. Björn Löwenadler and professor Solbritt Rantapää Dahlqvist”, says CEO Einar Pontén.
Download Press release (pdf) »